

Standing Group of Experts on Lumpy Skin Disease in Europe under the GF-TADs umbrella

Third meeting (LSD3) Istanbul, Turkey, 12-13 December 2016


LSD: Vaccine Quality

LSD Experts: Dr Kris De Clercq and Dr Annebel De Vleeschauwer EU Ref Lab Capripox viruses




LSD Vaccine Quality General Notes (Pro)

- Currently infected countries have been able to limit the spread or eradicate LSD with vaccination!
- Only live attenuated LSD vaccines are currently available
- Live attenuated vaccines provide good protection in case a homologous vaccine is used in combination with sufficient vaccination coverage (>80% needed) and a (re)vaccination policy of young animals and imported animals.




LSD Vaccine Quality General Notes (Con)

- None of the vaccines currently used in Europe has a marketing authorisation within the European Union or other European countries
- None of these vaccines is produced under GMP conditions
- None of these vaccines is produced with a QC system as described in the European Pharmacopoeia



LSD: Vaccination

An emergency vaccination in accordance with Article 19 of Directive 92/119/EEC may therefore only be carried out in accordance with Article 8 of Directive 2001/82/EC of the European Parliament and of the Council, which <u>permits Member States</u> to provisionally allow the use of immunological veterinary medicinal products without a marketing authorisation in the event of a serious epizootic disease.




Decision to use LSD vaccine: Member State – CVO

LSD Vaccine Quality

Decision to use LSD vaccine: Member State – CVO

Who is responsible for the Quality and Quality Control (QC) of the LSD vaccines used?



Vaccines In Europe Who is responsible for the Quality and Quality Control (QC) of the vaccines?

EMA - European Medicines Agency

Committee for Medicinal Products for Veterinary Use

(CVMP)





EDQM - European Directorate for the Quality of Medicines The European Pharmacopoeia (Ph. Eur.)









Vaccines In Europe Who is responsible for the Quality and Quality **Control (QC) of the vaccines?**

Member States **Belgium: Federal Agency for Medicines and Health Products**



OIE: Manual of Diagnostic Tests and Vaccines for **Terrestrial Animals** Oie enconsection and we



Manual of Diagnostic lest and Vaccines for Terrestrial Animals

2016



LSD Vaccines In Europe Who is responsible for the Quality and Quality Control (QC) of the vaccines?

In case of LSD vaccines






LSD Vaccine Quality Information

Vaccine Manufacturer Information: Dossier: License / Registration Marketing Authorisation Quality Control LSD Vaccine: Registration Dossier available outside Europe?

Tender for vaccine Purchase (EC/Country): Quality criteria Check criteria fulfilled? --> Needed?




LSD Vaccine Quality Control Needed?

Trust on Vaccine Manufacturer Information: LSD Vaccine: How much quality information or guarantees do you have now?

Field information on secondary effects after vaccine

- 'Neethling disease': <1% 10%
- Milkdrop 6-9 dpv correlated with fever
- Detection and isolation of Bluetongue virus from commercial vaccine batches







- -European Pharmacopeia 04/2013:0062 Vaccines for Veterinary Use
- -European Pharmacopeia 04/2013:50206 Evaluation of safety of veterinary vaccines and immunosera
- -European Pharmacopeia 04/2008:50207 Evaluation of efficacy of veterinary vaccines and immunosera
- -European Pharmacopeia 01/2008:50107 Viral safety
- -European Pharmacopeia 01/2008:20609 Abnormal toxicity
- -European Pharmacopeia 04/2011:20601 Sterility
- -European Pharmacopeia 01/2016:50204 Cell cultures for the production of veterinary vaccines
- -European Pharmacopeia 07/2009:50205 Substances of animal origin for the production of veterinary vaccines
- -OIE Chapter 1.1.8 Principles of veterinary vaccine production. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2016.
- -OIE Chapter 1.1.9 Tests of biological materials for sterility and freedom from contamination. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2016.
- -OIE Chapter 2.4.13 Lumpy Skin disease (Version adopted in May 2016).Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2016









2016

LSD Vaccine Quality Control

Production:

- Pilot batches: development, evaluation, improvements
- Master Seed (MS)






1. Master Seed Lot and Working Seed Lot 1.1. Description of the production

1.1.1. Identity of the vaccine strain

Confusing Kenyavac from JOVAC: Kenyan SGPV 0-240 and 180 strains despite the name the strain is LSDV (Tuppurainen et al., 2014; Vandenbussche et al., 2016)

- 1.1.2. Substrates for seed culture preparation and for production
 - sera, media, primary cells, cell cultures
 - freedom from extraneous agents




1. Master Seed Lot and Working Seed Lot

1.2. Freedom from extraneous agents

-Evidence of absence of <u>bacterial</u>, <u>fungal</u> or <u>mycoplasmal</u> contaminants

-Evidence of absence of <u>viral</u> contaminants


e.g. BTV, EHDV, BVD, BDV, SPPX, GTPX, Lentiviruses (Maedi-visna virus, Bovine leucosis virus)



1. Master Seed Lot and Working Seed Lot

1.3. Evaluation of <u>safety</u>

- 1.3.1 Laboratory studies using Master of Working seed lot of maximum titre
 - -Administration of one dose: at least eight animals per group
 - -One administration of an overdose: 10 doses, 8 young animals
 - -Reproductive Performance: use in pregnant animals
 - -Dissemination of vaccine strain in vaccinated animals
 - -Increase in virulence Reversion to virulence Spread of the vaccine strain
 - -Residues



1. Master Seed Lot and Working Seed Lot

- 1.4. Evaluation of <u>efficacy</u> using Working seed lot of minimum titre expected at the end of the period of validity
- Efficacy tests are carried out in the target species to show at least efficacy in protection against LSD upon viral challenge: a least 12 animals

-Additional evidence must support all the claims being made, e.g.

- -onset and duration of immunity
- -onset and duration of protection

-influence of passively acquired immunity


1. Master Seed Lot and Working Seed Lot

1.5. Stability

period of validity (shelf-life): periodical re-titration

1.6. Pharmacovigilance

Continuous monitoring of LSD vaccines used in the field



2. Batch controls


2.1. Description of the production

2.1.1. Identity of the vaccine strain

2.1.2. Substrates for batch preparation

2.2. Freedom from extraneous agents

- -Evidence of absence of <u>bacterial</u>, <u>fungal</u> or <u>mycoplasmal</u> contaminants
- -Evidence of absence of <u>viral</u> contaminants




2. Batch controls

- 2.3. Safety
- -For each batch at least one 'Administration of an overdose'
- -For each batch at least one Abnormal Toxicity test in mice

2.4 Efficacy

- -Potency test
- -Ascertain that virus titre per vaccine dose of the vaccine batch under control is higher than the minimum protective dose (virus titration)




2. Batch controls

2.5. Stability

period of validity (shelf-life): periodical re-titration

2.6. Pharmacovigilance

Continuous monitoring of LSD vaccines used in the field



LSD Vaccine Quality

Thank you

LSD Experts: Dr Kris De Clercq and Dr Annebel De Vleeschauwer

EU Ref Lab Capripox viruses



